Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coenzyme A persulfide is a small molecule and an experimental compound that acts as a possible in vivo inhibitor of mammalian short chain acyl-CoA dehydrogenase. It is a modified form of coenzyme A (CoA) where the terminal thiol group is replaced by a persulfide group. This modification imparts unique chemical properties, such as increased acidity and nucleophilicity compared to thiols, making it more reactive at physiological pH. Coenzyme A persulfide has been studied for its potential role in modulating metabolic pathways involving fatty acid oxidation and acetyl-CoA synthesis by inhibiting enzymes that utilize CoA or acyl-CoAs as substrates[1][2][6]. Its pharmacological action remains largely experimental, with no approved clinical indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coenzyme A persulfide.